Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2026 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

ceribell inc - CBLL

CBLL

Close Chg Chg %
20.37 -0.22 -1.08%

Closed Market

20.15

-0.22 (1.08%)

Volume: 219.04K

Last Updated:

May 6, 2026, 4:00 PM EDT

Trade Now

Company Overview: ceribell inc - CBLL

CBLL Key Data

Open

$20.38

 Day Range

19.82 - 20.41

52 Week Range

10.85 - 24.33

 Market Cap

$767.68M

Shares Outstanding

37.87M

 Public Float

24.35M

Beta

0.99

 Rev. Per Employee

N/A

P/E Ratio

N/A

 EPS

-$1.46

Yield

0.00%

 Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

240.90K

  

CBLL Performance

1 Week
 
 -1.71%
 
1 Month
 
 11.02%
 
3 Months
 
 0.00%
 
1 Year
 
 26.17%
 
5 Years
 
 N/A
 

CBLL Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 8
Full Ratings ➔

About ceribell inc - CBLL

Ceribell, Inc. is a commercial-stage medical technology company, which engages in the provision of transforming the diagnosis and management of patients with serious neurological conditions. Its products include Point-of-Care EEG, which enables early detection and management of suspected seizure patients, promoting precise patient care and hospital-wide efficiencies, Clarity, an AI algorithm that interprets EEG in real-time, providing bedside alerts and continuous monitoring for status epilepticus, and EEG Portal, which makes it easy to remotely review EEG in real-time with pre-annotated EEG insights. The company was founded by Xing Juan Chao, Josef Parvizi, and Chris Chafe on August 29, 2014 and is headquartered in Sunnyvale, CA.

CBLL At a Glance

Ceribell, Inc.
360 North Pastoria Avenue
Sunnyvale, California 94085
Phone 1-800-436-0826 Revenue 89.06M
Industry Medical Specialties Net Income -53,412,000.00
Sector Health Technology 2025 Sales Growth 36.09%
Fiscal Year-end 12 / 2026 Employees 327
View SEC Filings

CBLL Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio 8.998
Price to Book Ratio 5.292
Price to Cash Flow Ratio N/A
Enterprise Value to EBITDA -11.643
Enterprise Value to Sales 7.46
Total Debt to Enterprise Value 0.034

CBLL Efficiency

Revenue/Employee 272,363.914
Income Per Employee -163,339.45
Receivables Turnover 5.917
Total Asset Turnover 0.423

CBLL Liquidity

Current Ratio 9.615
Quick Ratio 9.235
Cash Ratio 8.299

CBLL Profitability

Gross Margin 87.886
Operating Margin -65.574
Pretax Margin -59.971
Net Margin -59.971
Return on Assets -25.361
Return on Equity -30.829
Return on Total Capital -30.072
Return on Invested Capital -27.493

CBLL Capital Structure

Total Debt to Total Equity 14.341
Total Debt to Total Capital 12.542
Total Debt to Total Assets 11.377
Long-Term Debt to Equity 13.629
Long-Term Debt to Total Capital 11.92
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Ceribell Inc - CBLL

Collapse All in section
All values USD millions. 2022 2023 2024 2025 5-year trend
Sales/Revenue
25.92M 45.23M 65.44M 89.06M
Sales Growth
- +74.47% +44.71% +36.09%
Cost of Goods Sold (COGS) incl D&A
4.43M 7.06M 8.69M 10.79M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
497.00K 847.00K 1.14M 1.34M
Depreciation
352.00K 509.00K 741.00K 1.04M
Amortization of Intangibles
145.00K 338.00K 400.00K 300.00K
COGS Growth
- +59.41% +23.11% +24.10%
Gross Income
21.49M 38.16M 56.75M 78.27M
Gross Income Growth
- +77.57% +48.70% +37.93%
Gross Profit Margin
+82.91% +84.38% +86.72% +87.89%
2022 2023 2024 2025 5-year trend
SG&A Expense
57.51M 68.20M 96.46M 136.68M
Research & Development
7.24M 8.99M 13.56M 19.14M
Other SG&A
50.27M 59.21M 82.90M 117.53M
SGA Growth
- +18.59% +41.43% +41.69%
Other Operating Expense
- - - -
-
Unusual Expense
- 175.00K (48.00K) 1.50M
EBIT after Unusual Expense
(36.20M) (29.99M) (41.21M) (58.40M)
Non Operating Income/Expense
637.00K 2.64M 2.74M 6.88M
Non-Operating Interest Income
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
1.60M 2.10M 1.99M 1.89M
Interest Expense Growth
- +30.88% -5.05% -5.12%
Gross Interest Expense
1.60M 2.10M 1.99M 1.89M
Interest Capitalized
- - - -
-
Pretax Income
(37.16M) (29.45M) (40.45M) (53.41M)
Pretax Income Growth
- +20.74% -37.35% -32.03%
Pretax Margin
-143.36% -65.13% -61.82% -59.97%
Income Tax
- - 2.00K 11.00K
-
Income Tax - Current - Domestic
- - - -
-
Income Tax - Current - Foreign
- - - -
-
Income Tax - Deferred - Domestic
- - - -
-
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(37.16M) (29.46M) (40.45M) (53.41M)
Minority Interest Expense
- - - -
-
Net Income
(37.16M) (29.46M) (40.45M) (53.41M)
Net Income Growth
- +20.72% -37.30% -32.03%
Net Margin Growth
-143.37% -65.15% -61.82% -59.97%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
(37.16M) (29.46M) (40.45M) (53.41M)
Preferred Dividends
- - - -
-
Net Income Available to Common
(37.16M) (29.46M) (40.45M) (53.41M)
EPS (Basic)
-1.0925 -0.8661 -1.1284 -1.4617
EPS (Basic) Growth
- +20.72% -30.29% -29.54%
Basic Shares Outstanding
34.02M 34.02M 35.85M 36.54M
EPS (Diluted)
-1.0925 -0.8661 -1.1284 -1.4617
EPS (Diluted) Growth
- +20.72% -30.29% -29.54%
Diluted Shares Outstanding
34.02M 34.02M 35.85M 36.54M
EBITDA
(35.52M) (29.19M) (38.57M) (57.06M)
EBITDA Growth
- +17.82% -32.11% -47.95%
EBITDA Margin
-137.04% -64.55% -58.93% -64.07%

Snapshot

Average Recommendation BUY Average Target Price 28.143
Number of Ratings 8 Current Quarters Estimate -0.39
FY Report Date 06 / 2026 Current Year's Estimate -1.456
Last Quarter’s Earnings -0.385 Median PE on CY Estimate N/A
Year Ago Earnings -1.46 Next Fiscal Year Estimate -1.006
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 8 8 8 8
Mean Estimate -0.39 -0.35 -1.46 -1.01
High Estimates -0.36 -0.31 -1.33 -0.68
Low Estimate -0.43 -0.42 -1.61 -1.39
Coefficient of Variance -7.11 -9.16 -6.58 -22.91

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 8 8 8
OVERWEIGHT 0 0 0
HOLD 0 0 0
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Buy Buy Buy

Insider Actions for Ceribell Inc - CBLL

Date Name Shares Transaction Value
Apr 9, 2026 Xing Juan Chao President and CEO; Director 851,793 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $4.7 per share 4,003,427.10
Apr 9, 2026 Xing Juan Chao President and CEO; Director 850,347 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $18.4 per share 15,646,384.80
Apr 9, 2026 Xing Juan Chao President and CEO; Director 293,048 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Apr 9, 2026 Xing Juan Chao President and CEO; Director 148,585 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Apr 9, 2026 Xing Juan Chao President and CEO; Director 850,347 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $18.4 per share 15,646,384.80
Apr 9, 2026 Xing Juan Chao President and CEO; Director 873,901 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $4.7 per share 4,107,334.70
Apr 9, 2026 Xing Juan Chao President and CEO; Director 850,347 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $18.4 per share 15,646,384.80
Mar 6, 2026 David Foehr Senior VP, Finance and PAO 17,550 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $17.8 per share 312,390.00
Mar 6, 2026 David Foehr Senior VP, Finance and PAO 17,550 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $17.8 per share 312,390.00
Mar 6, 2026 David Foehr Senior VP, Finance and PAO 52,885 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Mar 6, 2026 David Foehr Senior VP, Finance and PAO 18,707 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $4.7 per share 87,922.90
Mar 6, 2026 David Foehr Senior VP, Finance and PAO 20,953 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $4.7 per share 98,479.10
Mar 6, 2026 Rebecca B. Robertson Director 18,749 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $17.8 per share 333,732.20
Mar 6, 2026 David Foehr Senior VP, Finance and PAO 54,042 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Feb 24, 2026 Josef Parvizi Director 722,652 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $20.27 per share 14,648,156.04
Feb 20, 2026 Josef Parvizi Director 739,366 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $20 per share 14,787,320.00
Jan 8, 2026 Raymond Woo Chief Technology Officer 173,932 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $4.7 per share 817,480.40
Jan 8, 2026 Raymond Woo Chief Technology Officer 14,274 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Jan 8, 2026 Raymond Woo Chief Technology Officer 167,317 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $21.16 per share 3,540,427.72
Jan 8, 2026 Raymond Woo Chief Technology Officer 167,317 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $21.18 per share 3,543,774.06

Ceribell Inc in the News